Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Boston Scientific Corp ha un obiettivo di prezzo di consenso pari a $114.64, stabilito in base alle ultime valutazioni degli analisti di 25. Le ultime 3 valutazioni degli analisti sono state rilasciate da UBS, Raymond James y Oppenheimer il julio 24, 2025. Con un obiettivo di prezzo medio di $125.67 tra le UBS, Raymond James y Oppenheimer, c'è un implicito 19.12% upside per Boston Scientific Corp da queste valutazioni degli analisti.
1calculado a partir de las calificaciones de los analistas
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/24/2025 | 27.96% | UBS | $130 → $135 | Maintains | Buy | |||
07/24/2025 | 17.54% | Raymond James | $121 → $124 | Maintains | Strong Buy | |||
07/24/2025 | 11.85% | Oppenheimer | $110 → $118 | Maintains | Perform | |||
07/24/2025 | 17.54% | Wells Fargo | $118 → $124 | Maintains | Overweight | |||
07/24/2025 | 18.48% | Truist Securities | $120 → $125 | Maintains | Buy | |||
07/24/2025 | 16.59% | Baird | $117 → $123 | Maintains | Outperform | |||
07/24/2025 | 26.07% | Barclays | $125 → $133 | Maintains | Overweight | |||
06/16/2025 | 11.85% | Leerink Partners | → $118 | Initiates | → Outperform | |||
05/28/2025 | 9% | Needham | $115 → $115 | Reiterates | Buy → Buy | |||
05/22/2025 | 18.48% | Citigroup | $119 → $125 | Maintains | Buy | |||
05/16/2025 | 18.48% | Morgan Stanley | $120 → $125 | Maintains | Overweight | |||
04/25/2025 | 18.48% | Barclays | $118 → $125 | Maintains | Overweight | |||
04/24/2025 | 14.69% | Raymond James | $122 → $121 | Maintains | Strong Buy | |||
04/24/2025 | 9% | Needham | $113 → $115 | Maintains | Buy | |||
04/24/2025 | 13.74% | RBC Capital | $116 → $120 | Maintains | Outperform | |||
04/24/2025 | 10.9% | Truist Securities | $113 → $117 | Maintains | Buy | |||
04/24/2025 | 6.16% | Evercore ISI Group | $110 → $112 | Maintains | Outperform | |||
04/24/2025 | 13.74% | Baird | $115 → $120 | Maintains | Outperform | |||
04/23/2025 | 17.54% | BTIG | $120 → $124 | Maintains | Buy | |||
04/16/2025 | 7.11% | Needham | → $113 | Upgrade | Hold → Buy | |||
04/11/2025 | 7.11% | Truist Securities | $120 → $113 | Maintains | Buy | |||
03/03/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/10/2025 | 13.74% | Stifel | $115 → $120 | Maintains | Buy | |||
02/10/2025 | 11.85% | Barclays | $111 → $118 | Maintains | Overweight | |||
02/07/2025 | 23.22% | UBS | $105 → $130 | Maintains | Buy | |||
02/06/2025 | 13.74% | Truist Securities | $110 → $120 | Maintains | Buy | |||
02/06/2025 | 10.9% | Canaccord Genuity | $101 → $117 | Maintains | Buy | |||
02/06/2025 | 9% | Baird | $100 → $115 | Maintains | Outperform | |||
02/06/2025 | 15.64% | Raymond James | $119 → $122 | Maintains | Strong Buy | |||
02/06/2025 | 9.95% | RBC Capital | $105 → $116 | Maintains | Outperform | |||
02/06/2025 | 9% | Stifel | $100 → $115 | Maintains | Buy | |||
02/06/2025 | 11.85% | Wells Fargo | $100 → $118 | Maintains | Overweight | |||
02/06/2025 | 15.64% | Citigroup | $107 → $122 | Maintains | Buy | |||
02/06/2025 | 13.74% | Morgan Stanley | $100 → $120 | Maintains | Overweight | |||
02/06/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/03/2025 | 9% | Piper Sandler | $95 → $115 | Maintains | Overweight | |||
01/31/2025 | 12.8% | Raymond James | $101 → $119 | Maintains | Strong Buy | |||
12/30/2024 | -4.27% | BTIG | $97 → $101 | Maintains | Buy | |||
12/18/2024 | -0.47% | RBC Capital | $98 → $105 | Maintains | Outperform | |||
12/18/2024 | 4.27% | Truist Securities | $100 → $110 | Maintains | Buy | |||
12/16/2024 | 4.27% | JP Morgan | $100 → $110 | Maintains | Overweight | |||
12/12/2024 | 4.27% | TD Cowen | $100 → $110 | Maintains | Buy | |||
12/11/2024 | 1.42% | Citigroup | $98 → $107 | Maintains | Buy | |||
12/11/2024 | -5.21% | Wells Fargo | $98 → $100 | Maintains | Overweight | |||
12/09/2024 | -4.27% | Canaccord Genuity | $98 → $101 | Maintains | Buy | |||
11/27/2024 | — | Needham | — | Reiterates | → Hold | |||
11/18/2024 | — | Needham | — | Reiterates | → Hold | |||
10/31/2024 | — | Needham | — | Reiterates | → Hold | |||
10/24/2024 | -5.21% | Bernstein | $92 → $100 | Maintains | Outperform | |||
10/24/2024 | -5.21% | Morgan Stanley | $92 → $100 | Maintains | Overweight | |||
10/24/2024 | -7.11% | RBC Capital | $95 → $98 | Maintains | Outperform | |||
10/24/2024 | -7.11% | Wells Fargo | $87 → $98 | Maintains | Overweight | |||
10/24/2024 | -7.11% | Citigroup | $92 → $98 | Maintains | Buy | |||
10/24/2024 | -7.11% | Canaccord Genuity | $98 → $98 | Maintains | Buy | |||
10/24/2024 | 4.27% | Mizuho | $100 → $110 | Maintains | Outperform | |||
10/24/2024 | — | Needham | — | Reiterates | → Hold | |||
10/23/2024 | -8.06% | BTIG | $93 → $97 | Maintains | Buy | |||
10/22/2024 | -5.21% | B of A Securities | $90 → $100 | Maintains | Buy | |||
10/21/2024 | -5.21% | TD Cowen | $86 → $100 | Maintains | Buy | |||
10/21/2024 | -7.11% | Canaccord Genuity | $88 → $98 | Maintains | Buy | |||
10/18/2024 | -5.21% | Stifel | $85 → $100 | Maintains | Buy | |||
10/18/2024 | -18.48% | Needham | $86 → $86 | Downgrade | Buy → Hold | |||
10/15/2024 | -5.21% | Baird | $91 → $100 | Maintains | Outperform | |||
10/14/2024 | -11.85% | BTIG | $84 → $93 | Maintains | Buy | |||
10/14/2024 | -5.21% | Truist Securities | $90 → $100 | Maintains | Buy | |||
10/08/2024 | -9.95% | RBC Capital | $85 → $95 | Maintains | Outperform | |||
10/01/2024 | -14.69% | Evercore ISI Group | $82 → $90 | Maintains | Outperform | |||
09/04/2024 | -10.9% | Raymond James | $91 → $94 | Maintains | Strong Buy | |||
08/22/2024 | -12.8% | Citigroup | $90 → $92 | Maintains | Buy | |||
08/22/2024 | -18.48% | Barclays | $78 → $86 | Maintains | Overweight | |||
07/25/2024 | -13.74% | Raymond James | $85 → $91 | Maintains | Strong Buy | |||
07/25/2024 | -26.07% | Deutsche Bank | $73 → $78 | Maintains | Hold | |||
07/25/2024 | -19.43% | RBC Capital | $85 → $85 | Reiterates | Outperform → Outperform | |||
07/25/2024 | -19.43% | JP Morgan | $82 → $85 | Maintains | Overweight | |||
07/25/2024 | -16.59% | Canaccord Genuity | $83 → $88 | Maintains | Buy | |||
07/25/2024 | -13.74% | Baird | $90 → $91 | Maintains | Outperform | |||
07/25/2024 | -18.48% | Needham | $82 → $86 | Maintains | Buy | |||
07/16/2024 | -18.48% | TD Cowen | $77 → $86 | Maintains | Buy | |||
07/16/2024 | -14.69% | Truist Securities | $86 → $90 | Maintains | Buy | |||
07/15/2024 | -20.38% | BTIG | $80 → $84 | Maintains | Buy | |||
07/15/2024 | -12.8% | Morgan Stanley | $79 → $92 | Maintains | Overweight | |||
07/10/2024 | -14.69% | Citigroup | $87 → $90 | Maintains | Buy | |||
07/02/2024 | -23.22% | Evercore ISI Group | $78 → $81 | Maintains | Outperform | |||
06/18/2024 | -22.27% | Needham | $82 → $82 | Reiterates | Buy → Buy | |||
05/30/2024 | -14.69% | Goldman Sachs | → $90 | Initiates | → Buy | |||
05/28/2024 | -9.95% | Argus Research | $80 → $95 | Maintains | Buy | |||
05/22/2024 | -17.54% | Citigroup | $85 → $87 | Maintains | Buy | |||
05/15/2024 | -14.69% | Mizuho | $85 → $90 | Maintains | Buy | |||
04/26/2024 | -26.07% | Barclays | $70 → $78 | Maintains | Overweight | |||
04/25/2024 | -18.48% | Truist Securities | $79 → $86 | Maintains | Buy | |||
04/25/2024 | -19.43% | Citigroup | $79 → $85 | Maintains | Buy | |||
04/25/2024 | -30.81% | Deutsche Bank | $63 → $73 | Maintains | Hold | |||
04/25/2024 | -22.27% | JP Morgan | $72 → $82 | Maintains | Overweight | |||
04/25/2024 | -19.43% | Raymond James | $73 → $85 | Maintains | Strong Buy | |||
04/25/2024 | -22.27% | RBC Capital | $78 → $82 | Maintains | Outperform | |||
04/25/2024 | -19.43% | Mizuho | $80 → $85 | Maintains | Buy | |||
04/25/2024 | -14.69% | UBS | $74 → $90 | Maintains | Buy | |||
04/25/2024 | -22.27% | Wells Fargo | $72 → $82 | Maintains | Overweight | |||
04/25/2024 | -26.07% | Evercore ISI Group | $72 → $78 | Maintains | Outperform | |||
04/25/2024 | -20.38% | Baird | $79 → $84 | Maintains | Outperform |
El último precio objetivo de Boston Scientific (NYSE:BSX) fue comunicado por UBS el julio 24, 2025. La firma de analistas fijó un precio objetivo para $135.00 que espera BSX a rise dentro de 12 meses (un posible 27.96% upside). 68 firmas de analistas han reportado calificaciones en el último año.
La última calificación de analistas para Boston Scientific (NYSE:BSX) fue proporcionada por UBS, y Boston Scientific mantuvo su buy calificación.
La última revisión al alza de Boston Scientific Corp se produjo en abril 16, 2025, cuando Needham elevó su precio objetivo a $113. Needham anteriormente tenía a hold para Boston Scientific Corp.
La última revisión a la baja de Boston Scientific Corp se produjo en octubre 18, 2024, cuando Needham cambió su precio objetivo de $86 a $86 para Boston Scientific Corp.
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Boston Scientific, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Boston Scientific se registró el julio 24, 2025, por lo que la próxima calificación estará disponible en torno al julio 24, 2026.
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Boston Scientific (BSX) fue un mantuvo con un precio objetivo de $130.00 a $135.00. El precio actual al que cotiza Boston Scientific (BSX) es de $105.50, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.